No Detail Found!

Analysis of the effect of R-CHOP regimen of pegylated liposomal doxorubicin on elderly patients with stage Ⅲ-Ⅳ diffuse large B-cell lymphoma

Author(s)
Xiao Zhou Wuxi Taihu Lake Hospital, Department of Hematology & Oncology,Wuxi,China
Yaping Wang Wuxi Taihu Lake Hospital, Department of Hematology & Oncology,Wuxi,China
Xiangyong Li Wuxi Taihu Lake Hospital, Department of Hematology & Oncology,Wuxi,China
Abstract
To explore the effect of R-CHOP regimen of pegylated liposomal doxorubicin (PLD) on elderly stage ?-? diffuses large B-cell lymphoma (DLBCL). A retrospective analysis was conducted on the treatment information 80 elderly cases of stage III-IV DLBCL admitted to our hospital from April 2017 to April 2020. According to treatment methods, they were divided into experimental groups (40 cases, using R-CHOP with PLD) and controls group (40 cases, using the traditional R-CHOP regimen). We compared the treatment effect, survival rate, cardiotoxicity and adverse reactions of the patients. (1) The short-term degree of effectiveness treatment in the experimental group was 85%, which was not significantly different from 80% in other patients (p>0.05). (2) 2-year OS or PFS of experimental group were better more (p<0.01) and the treatment advantage of the experimental group increased with time. (3) Incidence of neutropenia and alopecia in experimental group was lower more (p<0.05). (4) Cardiotoxicity indexes of experimental group were lower (p<0.05). The PLD-containing R-CHOP regimen can improve the long-term inventory level elderly cases of stage III-IV DLBCL, reduce the incidence of grade IV neutropenia and alopecia, alleviate the cardiotoxicity caused by chemotherapy, and have better safety.
Publication Details
Page(s) 2455-2459
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 34, Issue: S6, Year: 2021

Request the full text from PASTIC

Keywords
Polyethylene glycol liposomal doxorubicin,
References
Araie H,Sakamaki I,Matsuda Y,Tai K,Ikegaya S,Itoh K,Kishi S,Oiwa K,Okura M,Tasaki T,Hosono N,Ueda T,Yamauchi T .2017 .3A comparison between R-THP-COP and R-CHOP regimens for the treatment of diffuse large B-cell lymphoma in old patients: A single-institution analysis. Intern Med, 56(18) : 2407-2413.
Cohen A,Spektor TM,Stampleman L,Bessudo A,Rosen PJ,Klein LM,Woliver T,Flam M,Eshaghian S,Nassir Y,Maluso T,Swift RA,Vescio R,Berenson JR .2018 .Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma. Br. J. Haematol., 180(1) : 60-70.
Fan H,Yang J,Liu L,Qiao Y,Wang M,Qiu L,Shi H,Xi H,Wang Y .2017 .Effect of serum albumin on the prognosis of elderly patients with stage 3-4 chronic kidney disease. Int. Urol. Nephrol., 49(5) : 859-865.
Fu Z,Zhu J,Zheng W,Liu W,Ying Z,Xie Y,Wang X,Lin N,Tu M,Ping L,Deng L,Zhang C,Ding N,Song Y .2014 .Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma. Cancer Cell Int, 14(1) : 5.
Hertzberg M,Gandhi MK,Trotman J,Butcher B,Taper J,Johnston A,Gill D,Ho SJ,Cull G,Fay K,Chong G,Grigg A,Lewis ID,Milliken S,Renwick W,Hahn U,Filshie R,Kannourakis G,Watson AM,Warburton P,Wirth A,Seymour JF,Hofman MS,Hicks RJ .2017 .Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. , 102(2) : 356-363.
Jeong JU,Chung WK,Nam TK,Yang DH,Ahn SJ,Song JY,Yoon MS,Kim YH .2017 .Treatment results of radiotherapy following CHOP or R-CHOP in limitedstage head-and-neck diffuse large B-cell lymphoma: A single institutional experience. Radiat. Oncol. J, 35(4) : 317-324.
Kanemasa Y,Shimoyama T,Sasaki Y,Tamura M,Sawada T,Omuro Y,Hishima T,Maeda Y .2017 .The impacts of initial and relative dose intensity of RCHOP on outcomes of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma, 58(3) : 736-739.
Kühnl A,Cunningham D,Counsell N,Hawkes EA,Qian W,Smith P,Chadwick N,Lawrie A,Mouncey P,Jack A,Pocock C,Ardeshna KM,Radford J,McMillan A,Davies J,Turner D,Kruger A,Johnson PW,Gambell J,Rosenwald A,Ott G,Horn H,Ziepert M,Pfreundschuh M,Linch D M .2017 .Outcome of elderly patients with diffuse large B-cell lymphoma treated with RCHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. , 28(7) : 1540-1546.
Lastra-German IK,Navarrete-Reyes AP,MejíaDomínguez NR,Agreda-Vásquez GP .2019 .Adjusted chemotherapy according to frailty status in elderly patients with diffuse large B-cell lymphoma: Experience from a single referral center in Mexico city. Clin Lymphoma Myeloma Leuk., 19(2) : e98-e106.
Liu P,Han Y,Jiang SY,He XH,Qin Y,Gui L,Zhou SY,Zhou LQ,Yang JL,Yang S,Wen TY,Shi YK .2019 .A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma. Chin .Med. J. (Engl)., 132(15) : 1807-1814.
Maude SL,Frey N,Shaw PA,Aplenc R,Barrett DM,Bunin NJ,Chew A,Gonzalez VE,Zheng Z,Lacey SF,Mahnke YD,Melenhorst JJ,Rheingold SR,Shen A,Teachey DT,Levine BL,June CH,Porter DL,Grupp SA .2014 .Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med, 371(16) : 1507-17.
Park S,Jo JC,Do YR,Yang DH,Lim SN,Lee WS,Kim WS,Lee HS,Hong DS,Kim HJ,Shin HJ .2019 .Multicenter phase 2 study of reduced-dose CHOP chemotherapy combined with rituximab for elderly patients with diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk., 19(3) : 149-156.
Prusila REI,Peroja P,Jantunen E,Turpeenniemi-Hujanen T,Kuittinen O .2019 .Treatment of diffuse large B-cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP16). Hematol Oncol., 37(2) : 136-142.
Shen QD,Zhu HY,Wang L,Fan L,Liang JH,Cao L,Wu W,Xia Y,Li JY,Xu W .2018 .Gemcitabineoxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: A single-arm, open-label, phase 2 trial. , 5(6) : e261-e269.
Takahashi A,Mishima Y,Yokoyama M,Inoue N,Kusano Y,Gunji T,Nitta H,Ueda K,Nishimura N,Tsuyama N,Takeuchi K,Terui Y,Hatake K Y .2017 .Efficacy of chemotherapy in extremely elderly patients with diffuse large B-cell lymphoma. Rinsho, 58(5) : 427-432.
Tanimura A,Hirai R,Nakamura M,Takeshita M,Hagiwara S,Miwa A .2018 .The prognostic impact of dose-attenuated R-CHOP therapy for elderly patients with diffuse Large B-cell lymphoma. Intern. Med, 57(24) : 3521-3528.
Wang J,Shang S,Li J,Deng H,Ouyang L,Xie H,Zhu H,Li Y,Zuo C Y .2020 .Cancer Manag Res. , 12 : 4999-5008.
Wohner N,Varga G,Szloboda P,Farkas P,Masszi A,Horvath L,Szombath G,Varkonyi J,Benedek S,Masszi T .2017 .Thalidomidkezelés relabált, diffúz nagy B-sejtes lymphomában idős betegekben. Három eset bemutatása [Thalidomide therapy in relapsed diffuse large B-cell lymphoma in elderly patients. Three cases. , 158(41) : 1642-1648.
Zhang XY,Liang JH,Wang L,Zhu HY,Wu W,Cao L,Fan L,Li JY,Xu W .2019 .DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma. J. Cancer Res. Clin. Oncol., 145(1) : 117-127.
Zhou T,Zhang Z,Luo F,Zhao Y,Hou X,Liu T,Wang K,Zhao H,Huang Y,Zhang L Y .2020 .Comparison of first-line treatments for patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis. JAMA Netw Open, 3(10) : e2015748.
0

Citations

0

Downloads

13

Views